High Concordance between ddPCR- and NGS-Based Quantification of Donor-Derived Cell-Free DNA Percentage after Kidney Transplantation
Two different lab methods for tracking transplant rejection using blood DNA produce nearly identical results, making testing more flexible and accessible.
This multi-center validation study demonstrates near-perfect concordance between ddPCR and NGS approaches to donor-derived cell-free DNA quantification in kidney transplant monitoring, supporting clinical interchangeability based on cost and availability. While not cancer-focused, the findings advance the analytical validation framework for cfDNA-based monitoring technologies that are also applied in oncology.
What the study was
- Study design
- Prospective validation study (method comparison)
- Population
- Kidney transplant recipients undergoing indication biopsy or stable follow-up (Heidelberg/Berlin centers)
- Sample size
- 254
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Clinical Chemistry
Why it surfaced
Solid validation study for cfDNA assay interchangeability; limited direct cancer relevance (transplant context) but methodologically relevant to liquid biopsy technology standardization. Downgraded from core watchlist relevance.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.